Cerulea Clinical Trials

Science and Research

Sandcat

This research project is testing an experimental treatment called RO7200220, an anti-IL6 monoclonal antibody, which aims to control the inflammation and remove the fluid that has built‑up within the retina in patients with UME.

Overview

Uveitis is a condition characterised by inflammation of the inside of the eye.

Some patients with uveitis can develop inflammation-related fluid in a delicate layer at the back of the eye called the retina.

This particular condition where inflammation-related fluid builds up in the retina is called Uveitic Macular Edema (UME).

This research project is testing an experimental treatment called RO7200220, an anti-IL6 monoclonal antibody, which aims to control the inflammation and remove the fluid that has built‑up within the retina in patients with UME.

The main current treatment for UME is steroids given as eye drops, tablets, or injections inside or around the eye.

Steroids can cause unwanted side‑effects, including increased eye pressure, clouding of the lens in the eye (cataract), and health problems outside of the eye, including hypertension and diabetes.

RO7200220 is not a steroid treatment and has been developed to avoid these problems.

The primary aim of this trial is to assess the safety and effectiveness of RO7200220 against no treatment (sham).

This one year study would require the eligible patient to attend for monthly visits during which they could receive intravitreal (eye) injections of RO7200220 or sham injections.

The sham procedure feels like a real drug injection but does not involve a needle being inserted into the eye, and nothing is injected into the eye.

For further information about this study please contact Cerulea on (03) 8638 5300 or emailinfo@ceruleaclinicaltrials.org.au

  • Principal Investigator
Professor Lyndell Lim

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.